Completed NA INTERVENTIONAL 1-arm NCT05273255

Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy

An Open Label Feasibility Study of Fecal Microbiota Transplantation (FMT) in Patients With Malignancies Not Responding to Cancer Immunotherapy (CI)

Sponsor: Michael Scharl

Conditions Cancer Fecal Microbiota Transplantation Immune Checkpoint Inhibitors Immunotherapy

Interventions Fecal Microbiota Transplantation (FMT)

Updated 8 times since 2022 Last updated: Mar 24, 2025 Started: Mar 14, 2022 Primary completion: Jan 4, 2024 Completion: Oct 24, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05273255, this NA trial focuses on Cancer and Fecal Microbiota Transplantation and remains completed. Sponsored by Michael Scharl, it has been updated 8 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Apr 2025 — Present [monthly]

Completed NA
Nov 2024 — Apr 2025 [monthly]

Completed NA

Status: Recruiting → Completed
Sep 2024 — Nov 2024 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Mar 2024 — Jul 2024 [monthly]

Recruiting NA

▶ Show 3 earlier versions

Jun 2023 — Mar 2024 [monthly]

Recruiting NA
Jul 2022 — Jun 2023 [monthly]

Recruiting NA
Apr 2022 — Jul 2022 [monthly]

Recruiting NA

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Michael Scharl

Data source: University of Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland